Speakers and advisors

Why Does GSK Contract with Healthcare Professionals?

GlaxoSmithKline works with healthcare professionals because they provide valuable knowledge, insight and experience in appropriate disease and therapy areas that are important to the company and the healthcare community. Our goal is to have programs that reflect our values – focus on the best interests of the patient, be transparent about our working relationships, operate with integrity, and respect those with whom we work and serve.

GSK is committed to offering quality speaker events for healthcare professionals about our medicines and the conditions they are approved to treat.  These programs led by healthcare professionals deliver important information, which can translate to improved patient care.

Healthcare professionals also work with GSK as advisors. Their knowledge and experience helps GSK understand trends in the delivery of healthcare and the evolving needs of patients and providers for more effective medicines and vaccines.

GSK’s has instituted a global Code of Conduct and related Standards of Conduct that specify the allowable circumstances under which we can work with healthcare professionals, and the types of information that can be provided. Our policies do not replace any regional or country level codes that may be more detailed and restrictive.

In the U.S., GSK conducts both a federal and state review to identify and exclude healthcare professionals from its speaker program who meet one or more of the following criteria (whether past or present):

• Identified as being an excluded individual or entity by the Office of the Inspector General (“OIG”);
• Identified as having been debarred by the Food and Drug Administration (“FDA”); and
• Identified as having received a professional sanction and/or disciplinary action from either a federal or state government agency or authority.

Since 2009, GSK has voluntarily and publicly reported its payments to US healthcare professionals for promotional speaking and advising services.

GSK is committed to providing as complete and accurate a disclosure as possible. However, despite our best efforts, from time to time errors can occur. As a result, we have established internal processes to continually review and validate our accuracy and voluntary disclosures, and to correct those records when errors are identified.

This disclosure report covers payments made by GSK to healthcare providers for speaking and consulting. Some medicines are
co-promoted by GSK and another company. For those medicines, this disclosure will not reflect payments by companies other than GSK.

Also, there were payments of $316,369 in 2010 and $350,000 in 2011 covered by a confidentiality agreement. These transactions are not reflected on the professional fee disclosure.

Healthcare professional fee disclosure

Download 1st, 2nd and 3rd quarter 2011 report (1.9MB PDF)

Download the 2010 report (724 KB PDF)

Download 2nd quarter through 4th quarter 2009 report (832 KB PDF)